Body composition and outcomes in dialysis patients and renal transplant recipients

Miklos Z Molnar 1,2, Kamyar Kalantar-Zadeh 1,3*

1 Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute, Harbor-UCLA Medical Center, Torrance, CA, USA
2 Institute of Pathophysiology, Semmelweis University, Budapest, Hungary
3 David Geffen School of Medicine, UCLA, Los Angeles, CA, USA

Abstract

Overweight (body mass index [BMI] = 25 - 30 kg/m²) and obesity (BMI ≥ 30 kg/m²) have become mass phenomena with a pronounced upward trend in prevalence in most countries throughout the world and are associated with increased cardiovascular risk and poor survival. In patients with end stage renal disease (ESRD) undergoing maintenance hemodialysis an ‘obesity paradox’ has been consistently reported, i.e., a high BMI is incrementally associated with better survival. Whereas this ‘reverse epidemiology’ of obesity is relatively consistent in maintenance hemodialysis patients, studies in peritoneal dialysis patients have yielded mixed results. Moreover, the effect of pre- and post-transplant obesity in kidney transplanted patients on long-term graft and patient survival has not been well established. However, BMI is unable to differentiate between adiposity and muscle mass and may not be an acceptable metric to assess the body composition of ESRD patients. Assessing lean body mass, in particular skeletal muscle, and fat mass separately are needed in ESRD patients using gold standard techniques such as imaging techniques. Alternatively, inexpensive and routinely measured surrogate markers such as serum creatinine, waist and hip circumference or mid-arm muscle circumference can be used. We have reviewed and summarized salient recent data pertaining to body composition and clinical outcomes about the association of survival and body composition in maintenance dialysis patients and kidney transplanted recipients.

Keywords:
Body Composition
Dialysis
Kidney transplantations

1. Background

Individuals with advanced (Stage 5) chronic kidney disease (CKD), also known as end-stage renal disease (ESRD), usually require renal replacement therapy to survive, either in form of maintenance dialysis treatment or kidney transplantation. Those who undergo maintenance dialysis treatment have a high annual mortality of approximately 20% to 23% in the United States and 15% to 20% in Europe, apparently mostly due to cardiovascular or infectious diseases (1). Despite decades of ongoing efforts towards correcting such conventional risk factors as obesity, hypertension, or hypercholesterolemia or...
other potential risk factors such as dialysis dose, anemia or hyperhomocysteinemia, dialysis patient survival has not improved substantially (1). Several recent randomized controlled trials in CKD patients have failed to show any survival benefit of increasing dialysis dose, lowering serum cholesterol, correcting hyperhomocysteinemia or improving anemia (2).

Whereas obesity is a risk factor for the development of CKD per se (3), many epidemiologic studies have indicated inverse associations between obesity or other cardiovascular risk factors and mortality in CKD and cardiac patients (4, 5). A higher death rate has been observed in CKD patients who have a low, rather than a high, body mass index (BMI) (6), blood pressure (7) or serum concentrations of cholesterol (8) or homocysteine (9); whereas high values of these risk factors are associated with improved survival. Other patients populations including those with heart failure (10), coronary artery disease (5, 11), or elderly individuals (12) also exhibit this so-called “obesity paradox”. However, most studies have not examined the relative contribution of fat vs. muscle mass or their changes over time to survival benefits of larger body size. Assessing muscle mass or lean body mass (LBM) is particularly difficult in large epidemiologic studies and require such elaborate tests of body composition as dual energy X-ray absorptiometry (DEXA) (13). Among biochemical markers of muscle mass, serum creatinine is most routinely measured, but its association with kidney function has hampered its utility as such (14). Nevertheless, in long-term dialysis patients with minimal or no residual renal function who undergo a stable dialysis treatment regimen, time-averaged serum creatinine concentration appear to be a more likely surrogate of muscle mass, and its changes over time may represent parallel changes in skeletal muscle mass (15, 16). Here, we summarized the salient findings of selected recent studies about the association of survival and body composition in ESRD patients on maintenance dialysis or kidney transplant recipients.

2. Body composition and survival in patients on maintenance dialysis

Measures of superior nutritional status, such as a high BMI in combination with normal or high muscle mass, are usually associated with greater survival in maintenance dialysis patients (17-22). In a study of incident peritoneal dialysis patients, the best survival was observed in those with high BMI and normal or high muscle mass (17). Unlike the general population, some, but not all, studies have shown that being overweight (perhaps a surrogate for “overnutrition”) may enhance survival among hemodialysis patients (18, 23-29). Given the consistency of the observations, there may be conditions in these and other chronic disease populations which render them more resistant to hardship and poor outcomes at higher BMI values. Several explanations have been suggested (30, 31), including a more stable hemodynamic status in obese individuals (32), higher concentration of tumor necrosis factor alpha receptors in obesity (33), neurohormonal alterations of obesity (34), endotoxin-lipoprotein interaction (35), differences in bone and mineral and vitamin D (36, 37), reverse causation (38), survival bias (39), time discrepancies among competitive risk factors (over- vs. under-nutrition) (39), and the overwhelming effect of malnutrition inflammation complex on traditional cardiovascular risks (40, 41). Since the almost 2/3 of maintenance hemodialysis patients in the US die within 5 years of commencing dialysis treatment (42), the long-term effects of conventional risk factors on future mortality may be overwhelmed by their potential short-term benefits or by other risk factors intrinsic to dialysis populations, such as under-nutrition and inflammation. Indeed, it may be that dialysis patients do not live long enough to die of the consequences of over-nutrition, since they die much faster from other health conditions such as protein-energy wasting (43-46). Hence, obesity, by providing more nutritional reserve, may protect them against early death (47).

We have summarized pertinent data of several leading studies in the field (Table 1). Hemodialysis patients appear to have a lower BMI than age- and sex-matched control subjects from the general population (48). In a recent matched analyses that compared the lipid profiles of 285 hemodialysis patients with those of 285 non-ESRD outpatients evaluated in the same medical center, matched one-to-one on age (± 5 years), sex, race, and diabetes mellitus status, the BMI was found to be significantly lower in the hemodialysis patients than in the non-ESRD control subjects (26.2 ± 6.0 compared with 31.5 ± 7.8; P < 0.001) (49). The Diaphane collaborative study group in France (50) was one of the first to report on the paradoxical observation of a lack of increase in mortality with high BMI in dialysis patients. This study included a cohort of 1453 younger, mostly non-diabetic, French hemodialysis patients followed between 1972 and 1978 in 33 French dialysis centers (50). Leavey et al. (24), while assessing the influence of many commonly used clinical variables on dialysis survival, confirmed the above lack of association between higher BMI values and increased mortality risk in a national sample of 3607 hemodialysis patients in the United States Renal Data System (USRDS). The mean BMI was 24.4 ± 5.3 in this study. In hazard regression models, low BMI was independently and significantly predictive of increased mortality. Kopple et al. evaluated 12965 hemodialysis patients and found that those patients with greater weight-for-height percentiles had lower mortality rates (47). After adjustment for clinical characteristics and laboratory measurements, the inverse relation between mortality rates and weight-for-height percentiles was still highly significant, particularly for patients in the lower 50th percentile of body weight-for-height (47). These findings suggest that not only BMI, but other measures of body size also correlate inversely with mortality in maintenance dialysis patients, independently of case-mix factors and comorbid conditions.
Recently, we studied a contemporary cohort of 121,762 thrice-weekly treated hemodialysis patients in a single large dialysis organization for up to 5 years and found that higher BMI, up to 45 kg/m², and higher serum creatinine, a likely surrogate of larger muscle mass, are each independently and incrementally associated with greater survival even after extensive multivariate adjustment for available surrogates of nutritional status and inflammation (22). Loss or gain in dry weight over time exhibited a graded association with greater mortality or survival, respectively, and so did changes in serum creatinine over time as a surrogate of changes in muscle mass. The concordant combination of the changes in these two body composition surrogates, if in the same direction, maintained the same graded death-predictability. However, among hemodialysis patients with a discordant combination; those who lost weight but gained muscle mass, represented by a parallel increase in serum creatinine, had a greater survival than those who gained weight but lost muscle, shown by a decrease in serum creatinine level over the same period of time. These associations were relatively robust and consistent across different demographic groups of hemodialysis patients (22).

Supporting to this observation, Noori et al. recently showed that higher mid-arm muscle circumference (MAMC) is a surrogate of larger lean body mass (LBM) and an independent predictor of better mental health and greater survival in hemodialysis patients (51). Adjusted death HRs were 1.00, 0.86, 0.69, and 0.63 for the first to fourth MAMC quartiles, respectively (51). Moreover, she examined 742 patients using near-infrared interchange to assess the LBM and fat mass (FM) (40). After adjustment for important co-variables, the highest quartiles of FM and LBM were associated with greater survival in women: HRs of 0.38 (95% CI: 0.20, 0.71) and 0.34 (95% CI: 0.17, 0.67), respectively (reference: first quartile). In men, the highest quartiles of FM and percentage FM but not of LBM were associated with greater survival: HRs of 0.51 (95% CI: 0.27, 0.96), 0.45 (95% CI: 0.23, 0.88), and 1.17 (95% CI: 0.60, 2.27), respectively (40). By comparison, obesity may be associated with worse survival outcomes among peritoneal dialysis patients (26, 52). However, opposite results were found when the body composition was taken into account. In a study of incident peritoneal dialysis patients, the best survival was observed in those with high BMI and normal or high muscle mass (17).

### Table 1. Summary of studies with large sample sizes (>1000 subjects) indicating a reverse epidemiology of obesity in maintenance hemodialysis (MHD) patients

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sample size</th>
<th>Follow-up period (yr)</th>
<th>Findings and source of data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degoulet et al. (1982)</td>
<td>1453</td>
<td>5</td>
<td>Higher death rate with lower BMI. Younger, mostly nondiabetic, French MHD patients.</td>
</tr>
<tr>
<td>Leavey et al. (1998)</td>
<td>3607</td>
<td>5</td>
<td>Higher mortality with lower BMI. USRDS data.</td>
</tr>
<tr>
<td>Fleischmann et al. (1999)</td>
<td>1346</td>
<td>1</td>
<td>Better survival with overweight and obesity. Mostly African American MHD patients. Mississippi patients only.</td>
</tr>
<tr>
<td>Koppel et al. (1999)</td>
<td>12965</td>
<td>1</td>
<td>Lower mortality with progressively higher weight-for-height; lowest mortality rates in overweight MHD patients. Data from Fresenius Medical Care.</td>
</tr>
<tr>
<td>Wolfe et al. (2000)</td>
<td>9165</td>
<td>2</td>
<td>Better survival in overweight and obese MHD patients. USRDS data.</td>
</tr>
<tr>
<td>Leavey et al. (2001)</td>
<td>9417</td>
<td>4</td>
<td>Mortality risk decreased with increasing BMI in both US and European MHD patients in the DOPPS, independent of the degree of sickness.</td>
</tr>
<tr>
<td>Port et al. (2002)</td>
<td>45967</td>
<td>2</td>
<td>The log of risk increased linearly for weight, weight-for-height, and BSA and was reverse J-shaped for weight/height and BMI. Data from Fresenius Medical Care.</td>
</tr>
<tr>
<td>Lowrie et al. (2002)</td>
<td>43334</td>
<td>1</td>
<td>The log of risk increased linearly for weight, weight-for-height, and BSA and was reverse J-shaped for weight/height and BMI. Data from Fresenius Medical Care.</td>
</tr>
<tr>
<td>Glanton et al. (2003)</td>
<td>151027</td>
<td>2</td>
<td>Paradoxical association between BMI and mortality was stronger in African American MHD patients. USRDS data.</td>
</tr>
<tr>
<td>Johansen et al. (2004)</td>
<td>418055</td>
<td>2</td>
<td>High BMI, adiposity, and fat mass were associated with increased survival in all but Asian American MHD patients. USRDS data.</td>
</tr>
<tr>
<td>Kalantar-Zadeh et al. (2005)</td>
<td>121762</td>
<td>2.5</td>
<td>Larger body size with more muscle mass appears associated with a higher survival rate. A discordant muscle gain with weight loss over time may confer more survival benefit than weight gain while losing muscle. Data from DaVita, Inc.</td>
</tr>
<tr>
<td>Molnar et al. (2010)</td>
<td>14632</td>
<td>3</td>
<td>Transplant-waitlisted hemodialysis patients with lower BMI or muscle mass and or unintentional weight or muscle loss were associated with higher mortality. Data from DaVita, Inc. and SRTR.</td>
</tr>
</tbody>
</table>
over, in one study of over 1300 hemodialysis patients, every one unit increase in the BMI was associated with a reduction of 30 percent in the relative risk of dying (23). This result may be confounded in part by race and gender, since African-American females have the highest BMI (53). This results has arrived the question it is the obesity-mortality association was modified by race?

3. Role of race in the association between body composition and survival

CKD is common and associated with major racial and ethnic disparities in the United States (US) (54-56). Approximately one-third of the 400,000 US dialysis patients are African Americans, even though they comprise only 14% of the US general population (57, 58). Hispanics compose close to 1/5 of the dialysis population (57, 58). Such disparities as disparities in income, education, diet, and lifestyle, co-morbid conditions and in healthcare have been implicated in the increased mortality of Blacks compared with Whites (59). The racial and ethnic discrepancies in CKD prevalence have persisted over the past decades. The incidence rates for dialysis patients for 2006 in the African American and Hispanic population continued to be 3.6 and 1.5 times, respectively, greater than among non-Hispanic whites (57, 58).

Notwithstanding the racial and ethnic differences in CKD rates, there are some encouraging facts pertaining to interaction of health outcomes and race/ethnicity. About two-thirds of all US dialysis patients die within 5 years of initiating maintenance dialysis treatment, higher than most cancers (59). Nonetheless, African American and Hispanic patients with end-stage renal disease (ESRD) have consistently greater survival over the past several decades than non-Hispanic Whites, with an death rate of 187 and 180 per 1000 patient-years at risk, respectively, compared to 207 per 1000 patient-years at risk for non-Hispanic whites (57, 58). The causes of these disparities remain largely unknown.

Discovering the factors responsible for survival advantages of African American and Hispanic dialysis patients may have major clinical and public health implications, not only for CKD patients but also for other populations with chronic disease states and poor survival. Understanding these factors might lead to methods for improving clinical outcomes in other groups of dialysis patients as well as in populations with other chronic disease states associated with poor survival (60). These issues are particularly time-sensitive for ESRD patients, since the imminent Bundling Payment for provision of medical care to dialysis patients in the US currently does not include an adjustor for race (61-63).

Some nutritional surrogates such as BMI are associated with both race and survival in maintenance hemodialysis patients, in whom higher BMI is associated with greater survival (21, 24, 47, 64). Glanton et al. reported 22% higher adjusted risk of obesity in African-Americans than in White-Americans (65). The same study also reported slightly higher hazard ratio for mortality in non-Caucasian than in Caucasian MHD patients with BMI < 22 kg/m² (65). Examining a large cohort of 124,029 adult hemodialysis patients, who were observed for up to 5 years during the first decade of the 21st century, African American and Hispanic patients had greater survival than Whites even after case-mix adjustment (66). After additional multivariate adjustment for surrogates of nutrition and inflammation, Hispanics had essentially the same mortality as White, whereas African Americans had a greater death risk compared to Hispanics or Whites. Our findings suggest that a healthier nutritional and inflammation-

---

Table 2. Summary of studies with large sample sizes (>1000 subjects) examined the association between pre-transplant obesity and post-transplant outcome

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sample size</th>
<th>Follow-up Period (yr)</th>
<th>Findings and source of data</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meier-Kreische et al. (2002) (94)</td>
<td>51927</td>
<td>Up to 10</td>
<td>U-shaped risk patterns such that both high and low BMI were related to increased risk of death and graft failure. USRDS data.</td>
</tr>
<tr>
<td>Gore et al. (2006) (95)</td>
<td>27377</td>
<td>Up to 7</td>
<td>Compared with normal weight patients, morbid obesity was independently associated with an increased risk of delayed graft function, prolonged hospitalization, acute rejection and decreased overall graft survival. Donor BMI did not affect overall graft survival. UNOS data.</td>
</tr>
<tr>
<td>Chang et al. (2007) (105)</td>
<td>5684</td>
<td>Up to 14</td>
<td>Obesity per se was not associated with poorer kidney transplant outcomes. Underweight was associated with late graft failure, mainly due to chronic allograft nephropathy. Australian and New Zealand Dialysis and Transplant (ANZDATA) Registry.</td>
</tr>
<tr>
<td>Marcin et al. (2007) (106)</td>
<td>1000</td>
<td>10</td>
<td>Pre-transplant high body mass and 1-year post-transplant weight gain were not risk factors for graft or patient survival. Single center.</td>
</tr>
<tr>
<td>Streja, Molnar et al. (2011) (93)</td>
<td>10090</td>
<td>2.5</td>
<td>Pre-transplant obesity does not appear associated with poor post-transplant outcomes. Larger pre-transplant muscle mass, reflected by higher pre-transplant serum creatinine level, is associated with greater post-transplant graft and patient survival. DaVita, Inc. and SRTR.</td>
</tr>
</tbody>
</table>
tory status is the main cause of the survival advantages of minorities who undergo hemodialysis treatment (66). Additionally, we found that obesity, as measured by BMI, was associated with greater survival in MHD patients of all races and ethnicity, but different patterns were observed across the three mutually exclusive racial and ethnic groups (67). The survival advantage of obesity was most prominent among Blacks. Our analyses suggest a protective but differential role for higher BMI across racial and ethnic groups of hemodialysis patients (67).

4. Body composition and survival in wait-listed dialysis patients

Kidney transplantation is the treatment of choice in patients with ESRD, since patients with functioning renal grafts have both survival benefits (68) and better quality of life (69) compared to transplant waitlisted patients on maintenance dialysis. Approximately 80,000 (20%) of the 400,000 US dialysis patients are currently on transplant waiting lists, although each year only ~16,500 of these patients receive a renal transplant (70, 71). At half of these patients receive a deceased kidney, which currently requires a wait period of 3 to 6 years in most regions of the United State (70). During this period, up to 40% of the transplant-waitlisted dialysis patients die (72).

Overweight and obesity are highly prevalent in patients at the time of kidney transplantation (73). Indeed, most transplant centers in US may suspend wait-listing of obese patients with a BMI above 30 or 35 kg/m² and refer them for weight reduction procedures such as bariatric surgery as a contingency for the transplant surgery (74). In a recent report BMI≥35 kg/m² was the third most common reason to deny patient active transplant-wait-listing, affecting approximately 10% of potential renal transplant candidates (75). However, consequences of obesity or changes in weight during the period of wait-listing, which usually last 4 to 7 years in the United States, remain unclear (76, 77). Weight changes prior to transplantation may be transient, especially since most renal transplant recipients experience weight gain following a successful kidney transplant (78). Hence, weight loss before transplantation might not alleviate the risk of obesity after transplantation. In recent study, by linking the 6-year (7/2001-6/2007) national databases of a large dialysis organization and the Scientific Registry of Transplant Recipients, we identified 14,632 waitlisted hemodialysis patients without kidney transplantation (79). Low BMI or serum creatinine, as a surrogate marker of muscle mass and their decrease over time are associated with increased death risk in transplant waitlisted hemodialysis patients. A 20% higher death risk is observed in patients losing more than 5 kg of dry weight compared to patients with stable weight over time. Compared to the lowest serum creatinine quintile, the 4th and 5th quintiles had death hazard ratio of 0.75 (0.66-0.86) and 0.57 (0.49-0.66), respectively. Controlled trials are needed to examine the effects of intentional pre-transplant weight loss on pre- and post-transplant outcomes.

5. Body composition and survival in kidney transplanted patients

Role of pre-transplant obesity

An obesity paradox has been consistently observed in dialysis patients, but conflicting data have been published about the association of pre-transplant body size and weight with post-transplant graft and patient survival in renal transplant recipients (Table 2). Early studies had reported poorer kidney transplant outcomes in obese dialysis patients (80-83) mainly due to cardiovascular (76) and infectious complications such as surgical wound infections (84). More recent studies, however, have reported that weight change prior to transplantation did not correlate with graft loss and death after kidney transplantation (78), even though obese recipients develop diabetes mellitus or surgical complications more frequently (84-88). Many transplant centers exclude or suspend obese patients with a BMI > 30 or > 35 kg/m² from the transplant waitlist and refer them for weight reduction strategies such as bariatric surgery (74). However, clinical trials of bariatric surgery in populations without kidney disease indicate comparable weight loss but higher post-surgery mortality (89). In a recent report BMI≥35 kg/m² was the third most common reason to deny transplant wait-listing and affecting 10% of potential renal transplant candidates (75). Since the long term consequences of obesity after transplantation remain unclear (76, 77), it is important to address the potential association between pre-transplant body composition and post-transplant outcomes.

Previous studies of obesity in kidney transplant recipient used solely BMI to define obesity (80-83), but BMI is unable to differentiate between adiposity and muscle mass (90). Reduced muscle mass (sarcopenia) is a predictor of mortality in dialysis patients (51). To better characterize patients’ nutritional status, additional parameters such as waist circumference or serum creatinine have been suggested (22, 31, 40, 51, 91, 92). Indeed, in maintenance dialysis patients with minimal residual function under steady-state serum creatinine may better reflect muscle mass compared to BMI (22, 31, 40, 51, 92). Recently we examined a large and contemporary national data of over 10,000 renal transplant recipients, pre-transplant low BMI showed a trend towards higher post-transplant mortality, and lower pre-transplant serum creatinine level, a potential surrogate of sarcopenia, was associated with the unfavorable post-transplant outcomes (93). We categorized renal transplant recipients into four groups, based on their pre-transplant BMI and serum creatinine levels being above or below the median value of these measure (26 kg/m² and 10.5 mg/dL, respectively), leading to 2 concordant (high/high and low/low) and 2 discordant (high/low and low/high) groups (Figure 1). The post-transplant death and graft failure hazard ratios are shown in Figure 1. Compared to the low creatinine and
Low BMI groups (reference), the groups with high creatinine and high BMI had 34% lower adjusted death risk (HR: 0.73, [0.57-0.90]) (Figure 1). Adjustment levels in the Figure 1 present Case-mix adjusted models that included BMI/creatinine, entry calendar quarter, age, sex, race and ethnicity, diabetes mellitus, dialysis vintage, primary insurance, marital status, the standardized mortality ratio of the dialysis clinic during entry quarter, dialysis dose as indicated by Kt/V (single pool), presence or absence of a dialysis catheter, and residual renal function during the entry quarter, i.e. urinary urea clearance, Case-mix, malnutrition-inflammation-complex syndrome (MICS) adjusted models which included all of the covariates in the case-mix model as well as 10 surrogates of nutritional status and inflammation, including 11 laboratory variables with known association with clinical outcomes in MHD patients, i.e. normalized protein catabolic rate (nPCR) as an indicator of daily protein intake, also known as the normalized protein nitrogen appearance (nPNA) and an indicator of daily protein intake, also known as the normalized protein nitrogen appearance (nPNA) and serum or blood concentrations of albumin, TIBC, ferritin, phosphorus, calcium, bicarbonate, peripheral white blood cell count (WBC), lymphocyte percentage, and hemoglobin, and Case-mix, malnutrition-inflammation-complex syndrome (MICS) and transplant data adjusted models which included all of the covariates in the case-mix model and MICS model as well as 5 transplant-related data, i.e., donor type (deceased or living), donor age, race, gender, causality and tacrolimus was available. Moreover, the latter cohort was younger and had less diabetic and African-American patients. Additional studies are needed to better understand the association between obesity, muscle mass and other body compositions and transplant outcomes.

### Obesity after transplantation

Obesity contributes to an adverse cardiovascular risk profile and may also be involved in the pathogenesis of allograft dysfunction (96). The deleterious effects of obesity on the kidney are in part mediated by associated cardiovascular risk factors such as diabetes mellitus, hypertension, dyslipidemia, and insulin resistance (97, 98). Recently, Hoogeveen et al. reported that one year post-transplant BMI and BMI increment are more strongly related to death and graft failure than pre-transplant BMI among kidney transplant recipients (99). Patients with post-transplant BMI more than 30 kg/m² compared with a normal BMI have approximately 20% to 40% higher risk for death and graft failure (99). Previous studies of obesity in kidney transplant recipients used solely BMI to define obesity (80-83), but BMI is unable to differentiate between adiposity and muscle mass (90). We also proved that higher BMI and waist circumference display opposite associations with mortality in kidney transplant recipients (91). Waist circumference appears to be a better prognostic marker for obesity than BMI. Unadjusted death hazard ratios (95%CI) associated with one standard deviation higher BMI and waist circumference were 0.94 (0.78, 1.13), p = 0.5 and 1.20 (1.00, 1.45), p = 0.05, respectively. Higher BMI was associated with lower mortality after adjustment for waist circumference (0.48 [0.34, 0.69], p < 0.001), and higher waist circumference was more strongly associated with higher mortality after adjustment for BMI (2.18 [1.55-3.08], p < 0.001) (91).

In summary, we conclude that overweight and obesity have become mass, that are often associated with increased cardiovascular risk and poor survival in the general population appear to confer survival advantage in ESRD patients. This so-called ‘obesity paradox’ has been consistently reported in other chronic disease states. Whereas the ‘reverse epidemiology’ of obesity is relatively consistent in maintenance hemodialysis patients, studies in peritoneal dialysis patients have yielded mixed results. The effect of pre- and post-transplant obesity in kidney transplanted patients on long-term graft and patient survival appears to be more complicated. The BMI is unable to differentiate accurately between adiposity and muscle mass, in patients with ESRD. Assessing lean body mass, in particular skeletal muscle, and fat mass separately are needed in ESRD patients using gold standard techniques such as imaging techniques. Alternatively,
inexpensive and routinely measured surrogate markers such as serum creatinine, waist and hip circumference or mid-arm muscle circumference can be used.

Financial support

The paper was supported by Dr. Kalantar-Zadeh’s research grants from the American Heart Association grant (0655776Y), the National Institute of Diabetes, Digestive and Kidney Disease of the National Institute of Health (R01 DK078106); a research grant from DaVita Clinical Research and a philanthropic grant from Mr. Harold Simmons. Additionally, Dr. Miklos Zsolt Molnar received grants from the National Research Fund (NKTH-OTKA-EU 7KP-HUMAN-MB08-A-81231), which was also supported by the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (2008-2010) and Hungarian Kidney Foundation, and is a recipient of the Hungarian Eötvös Foundation, and is a recipient of the Hungarian Eötvös Académie of Sciences (2008-2011) and Hungarian Kidney Disease Who Are Not Yet on Dialysis: Effects of Case Mix and weight change over time with cardiovascular survival in hemodialysis patients. Mayo Clin Proc. 2010;85(3):290-301.

Conflict of interest

Dr. Kalantar-Zadeh is the medical director of DaVita Harbor-UCLA/MFI in Long Beach, CA. MZ Molnar has not declared any conflict of interest.

Acknowledgments

We express our sincere appreciation to the teammates in nearly 1600 DaVita clinics who work every day, not only to take care of patients but also to ensure the extensive data collection on which our work is based. We thank DaVita Clinical Research® (DCR) for providing the clinical data, analysis and review for this research project and for advancing the knowledge and practice of kidney care.

References


